Oxcia AB (publ) held an Extraordinary General Meeting on 24 September 2026. Below is a summary of the resolutions adopted.
The General Meeting resolved, in accordance with the Board of Directors’ proposal, on a directed issue of convertible instruments to Thomas Helleday. Thomas Helleday will invest a total of SEK 15,000,000 in the company. Of this amount, SEK 10,000,000 will be invested through the resolved convertible issue, and he has undertaken to invest the remaining SEK 5,000,000 in the next issue.
The General Meeting also resolved, in accordance with the Board of Directors’ proposal, to authorise the Board of Directors, on one or more occasions until the next Annual General Meeting and within the limits of the Articles of Association, to resolve on issues of shares, warrants and/or convertible instruments, with or without deviation from the shareholders’ preferential rights. The two authorisations concern a general issue authorisation and an authorisation for ownership-spreading issues.
For more information contact:
Ulrika Warpman Berglund, CEO, Oxcia AB (publ)
Telephone: +46 (0) 73 270 9605
ulrika.warpmanberglund@oxcia.com
About Oxcia
Oxcia AB is a clinical-stage biotech company pioneering therapies that target key drivers of many diseases, using its proprietary O2-DDR platform (Oxidative stress, Oxidative DNA damage, and DNA Damage Response (DDR)). The platform has so far generated two first-in-class drug candidates: OXC-101, currently in clinical development for acute myeloid leukemia with both FDA and EMA Orphan Drug Designations, and OXC-201, a novel treatment for idiopathic pulmonary fibrosis supported by European Innovation Council funding. By addressing major unmet medical needs through a differentiated scientific approach, Oxcia aims to deliver transformative therapies to make life less short, creating significant value for patients and investors.